StockData
Bioxytran, Inc logo

Bioxytran, Inc (BIXT) stock

BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30
$0.02−0.00 (-3.95%)

Close on Oct 19, 2026Market cap $2.56MP/E –Yield –

Bioxytran operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Bioxytran's operating income for the twelve months ending Jun 30, 2026 was -$3.69M. For fiscal 2025 it was -$1.84M. The highest annual figure on record is -$215.11K in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.84M–
FY2024Dec 31, 2024-$2.22M–
FY2023Dec 31, 2023-$3.80M–
FY2022Dec 31, 2022-$2.44M–
FY2021Dec 31, 2021-$4.21M–
FY2020Dec 31, 2020-$1.27M–
FY2019Dec 31, 2019-$1.63M–
FY2018Dec 31, 2018-$215.11K–
FY2017Dec 31, 2017-$310.59K–
FY2016Dec 31, 2016-$671.28K–
FY2015Dec 31, 2015-$2.09M–
FY2014Dec 31, 2014-$1.28M–
FY2013Dec 31, 2013-$1.97M–
FY2012Dec 31, 2012-$2.29M–
FY2011Dec 31, 2011-$4.43M–
FY2010Dec 31, 2010-$329.03K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$654.60K–
Q1 FY2026Mar 31, 2026-$1.93M–
Q4 FY2025Dec 31, 2025-$607.29K–
Q3 FY2025Sep 30, 2025-$496.01K–
Q2 FY2025Jun 30, 2025-$224.08K–
Q1 FY2025Mar 31, 2025-$515.14K–
Q4 FY2024Dec 31, 2024-$488.31K–
Q3 FY2024Sep 30, 2024-$346.20K–
Q2 FY2024Jun 30, 2024-$609.32K–
Q1 FY2024Mar 31, 2024-$779.23K–
Q4 FY2023Dec 31, 2023-$1.01M–
Q3 FY2023Sep 30, 2023-$985.47K-7027.7%
Q2 FY2023Jun 30, 2023-$1.06M–
Q1 FY2023Mar 31, 2023-$750.24K–
Q4 FY2022Dec 31, 2022-$1.09M–
Q3 FY2022Sep 30, 2022$14.23K–
Q2 FY2022Jun 30, 2022-$537.22K–
Q1 FY2022Mar 31, 2022-$819.11K–
Q4 FY2021Dec 31, 2021-$935.96K–
Q3 FY2021Sep 30, 2021-$547.24K–
Q2 FY2021Jun 30, 2021-$1.04M–
Q1 FY2021Mar 31, 2021-$1.69M–
Q4 FY2020Dec 31, 2020-$776.30K–
Q3 FY2020Sep 30, 2020-$114.45K–
Q2 FY2020Jun 30, 2020-$111.91K–
Q1 FY2020Mar 31, 2020-$266.04K–
Q4 FY2019Dec 31, 2019-$499.66K–
Q3 FY2019Sep 30, 2019-$850.32K–
Q2 FY2019Jun 30, 2019-$106.50K–
Q1 FY2019Mar 31, 2019-$129.63K–
Q4 FY2018Dec 31, 2018-$166.64K–
Q3 FY2018Sep 30, 2018-$47.52K-193.5%
Q2 FY2018Jun 30, 2018-$275–
Q1 FY2018Mar 31, 2018-$670–
Q4 FY2017Dec 31, 2017-$86.41K-163.0%
Q3 FY2017Sep 30, 2017$50.83K–
Q2 FY2017Jun 30, 2017-$258.47K–
Q1 FY2017Mar 31, 2017-$62.64K–
Q4 FY2016Dec 31, 2016$137.23K–
Q3 FY2016Sep 30, 2016-$212.04K–

More Bioxytran figures

See a number that looks wrong?